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Introduction: There remains a significant therapeutic need for 
small-cell lung cancer (SCLC). We and others have reported high 
frequency of copy number gains in cytogenetic bands encoding 
fibroblast growth factor receptor 1 (FGFR1) in SCLC tumors and 
cell lines.
Methods: Thirteen SCLC cell lines and 68 SCLC patient tumor 
samples were studied for FGFR1 amplification. Growth inhibition 
assays were performed using PD173074, a pan-FGFR inhibitor to 
determine the correlation between FGFR1 expression and drug 
sensitivity.
Results: We did not detect FGFR1 mutations in SCLC cell lines. 
Focal amplification of FGFR1 gene was found in five tumor 
samples (7%), with high-level focal amplification in only one 
tumor sample (1%). Amplification owing to polysomy of chro-
mosome 8, where FGFR1 locates, was observed in 22 tumor sam-
ples (32%). There was no correlation between FGFR1 gene copy 
number and messenger RNA expression or protein expression in 
SCLC cells. FGFR inhibitor sensitivity correlated with FGFR1 
copy number determined by real-time polymerase chain reaction 
assay (r= −0.79; p = 0.01).
Conclusion: FGFR1 gene mutations and focal amplification 
are rare in SCLC, but polysomy of chromosome 8 is relatively 
common. FGFR1 copy number gain predicts sensitivity to 
FGFR inhibition, and FGFR expression correlates inversely with 
chemosensitivity.
Key Words: Small-cell lung cancer, FGFR1, Focal amplification, 
Copy number gain.
(J Thorac Oncol. 2014;9: 567–571)
Small-cell lung cancer (SCLC) comprises 13% of all lung cancers.1 Despite extensive research over the last two 
decades, treatment for SCLC has not improved significantly 
and prognosis remains poor.2 Genetic characterization of 
driver mutations could potentially offer effective drug targets 
and novel therapies in SCLC. Although previous studies have 
reported recurrent genetic alterations in SCLC,3–5 therapeuti-
cally tractable targets have so far been elusive.
Fibroblast growth factors and fibroblast growth factor 
receptors (FGFR) play essential roles in regulation of normal 
cell proliferation, survival, migration, and differentiation.6 The 
FGFR tyrosine kinase family comprises four kinases: FGFR1, 
FGFR2, FGFR3, and FGFR4. FGFR1 amplification has been 
reported in 22% of squamous cell lung carcinoma and may 
predict sensitivity to FGFR inhibition.7 The fibroblast growth 
factor signaling pathway may influence growth of SCLC. 
FGFR inhibition impairs SCLC growth in vitro and in vivo, 
reduces intratumor proliferation, and increases apoptosis.8 We 
and others have reported high copy number gains (CNGs) in 
cytogenetic bands encoding FGFR1 in SCLC cell lines and 
tumors.4,5 High CNGs in some of the samples suggest a role 
for FGFR1 as a potential therapeutic target in a subgroup of 
SCLC. In this study, we sought to further characterize the role 
of FGFR1 in SCLC.
PATIENTS AND METHODS
Tumor Samples, Tissue Microarray, 
and Cancer Cell Lines
Thirteen SCLC cell lines and 68 SCLC tumor samples 
were studied. Use of human samples was approved by the 
National Cancer Institute (NCI) Institutional Review Board. 
Details of cells and tumors are described in the Supplementary 
Materials and Methods (Supplementary Digital Content 1, 
http://links.lww.com/JTO/A534).
Array Comparative Genomic 
Hybridization Analysis
We performed array comparative genomic hybridization 
(aCGH) analysis on five patient samples from the NCI cohort. 
aCGH was performed and analyzed as described previously.5 A 
reference genomic DNA was used for hybridization. Data analy-
sis was performed using Nexus 4.0 software (Biodiscovery Inc., 
Hawthorne, CA). CNG and loss of the FGFR1 gene were defined 
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if the log
2
 ratio values of sample DNA/reference genomic DNA 
were more than 0.2 and less than −0.2, respectively.
Sequencing
Exons 2 to 18 of FGFR1 gene were sequenced in 13 
SCLC cell lines as described in the Supplementary Materials 
and Methods (Supplementary Digital Content 1, http://links.
lww.com/JTO/A534).
Real-Time Polymerase Chain Reaction
The messenger RNA (mRNA) expression of FGFR1 
gene and the copy numbers of the FGFR1 gene in SCLC cells 
were evaluated using the Taqman gene expression assay and 
Taqman copy number assay, respectively (Applied Biosystems, 
Foster City, CA), following manufacturer’s instruction. Details 
of the method are described in the Supplementary Materials 
and Methods (Supplementary Digital Content 1, http://links.
lww.com/JTO/A534).
Western Blot
Western blotting was performed as previously 
described.9 Anti-FGFR1 antibody was obtained from Abcam 
(Cambridge, United Kingdom), anti-p-FGFR antibody 
was from Cell Signaling Technology (Danvers, MA), and 
 anti-Actin antibody was from Sigma-Aldrich (St. Louis, MO). 
Semiquantification of signals of Western blot was analyzed 
by Image J software (National Institutes of Health, Bethesda, 
MD). FGFR1 protein expression was normalized by actin 
protein expression and then calibrated by the expression level 
of the H69 cells before further analysis.
Growth Inhibition Assays
The concentration that inhibits 50% to drugs in SCLC 
cells was determined as described in the Supplementary 
Materials and Methods (Supplementary Digital Content 1, 
http://links.lww.com/JTO/A534).
Fluorescence In Situ Hybridization 
for the FGFR1 Gene
Fluorescence in situ hybridization (FISH) assays were 
performed on 5 μm formalin-fixed paraffin-embedded tumor 
sections using a laboratory standardized protocol with slight 
modifications.10 Details of the method are described in the 
Supplementary Materials and Methods (Supplementary Digital 
Content 1, http://links.lww.com/JTO/A534). CNG was defined as 
red FGFR1 signals with the corresponding control chromosome 
enumeration probes (CEP8) more than or equal to four copies per 
cell in more than 20% of cells. Focal amplification was defined 
if the ratio of the FGFR1 gene to the CEP8 was more than 2 
( low-level amplification 2–4; high-level amplification >4).
Statistical Analysis
Correlation between variables was analyzed using 
Spearman’s method, and p values less than 0.05 were regarded 
as significant.
FIGURE 1.  FGFR1 in SCLC cells. A, 
FGFR1 protein expression in SCLC 
cells. G, copy number gain; N, copy 
number normal; L, copy number 
loss. The numbers indicate the copy 
number of the FGFR1 gene deter-
mined by the real-time PCR assay. B, 
Correlation of FGFR1 copy number 
assessed by real-time PCR and mRNA 
expression and protein expression. 
C, Correlation of concentration that 
inhibits 50% to PD173074 and  
FGFR1 copy number assessed by 
real-time PCR assay, FGFR1 mRNA 
expression, or FGFR1 protein expres-
sion. FGFR1, fibroblast growth factor 
receptor 1; SCLC, small-cell lung can-
cer; PCR, polymerase chain reaction; 
mRNA, messenger RNA.
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RESULTS
Expression of FGFR1 Is Unrelated 
to Gene Copy Number
We previously reported genetic alterations of 13 
SCLC cell lines using aCGH assay.5 We further determined 
the copy number of the FGFR1 gene using real-time poly-
merase chain reaction assay and evaluated whether the copy 
number alteration of the FGFR1 gene is associated with its 
protein expression (Fig. 1A). Whereas the protein expres-
sion of the FGFR1 gene was related to its mRNA expression, 
protein or mRNA expression of the FGFR1 gene in SCLC 
cells was unrelated to its gene copy number (Fig. 1B). As the 
 anti-p-FGFR antibody is not FGFR1 specific, we failed to 
observe correlation between expression of p-FGFR and copy 
number of the FGFR1 gene (r = −0.19, p = 0.66), FGFR1 
FIGURE 2. FGFR1 in SCLC tumors. A, 
Dual-color fluorescence in situ hybridiza-
tion showing FGFR1 (red fluorescence sig-
nal) gene copy number variations along 
with the reference chromosome 8 centro-
meric probe (aqua fluorescence signal) in 
SCLC cell lines and primary tumors. Left: 
Ideogram of chromosome 8 with  
FGFR1 gene mapped to 8p12-p11.23 
chromosomal region. Normal peripheral 
blood lymphocytes showing two copies of 
FGFR1 gene on interphase and metaphase 
cells. B, Genome-wide frequency of copy 
number alterations. Gains and losses are 
shown in blue and red, respectively. C, 
High-resolution analysis showing copy 
number alterations in chromosome 8p 
where FGFR1 is located of patient samples 
3 and 5 which had chromosome 8p 
polysomy. FGFR1, fibroblast growth factor 
receptor 1; SCLC, small-cell lung cancer.
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mRNA expression (r = −0.31, p = 0.45), and FGFR1 protein 
expression (r = −0.34, p = 0.42). We sequenced the exons 2 to 
18 of the FGFR1 gene in 13 SCLC cell lines, and no mutation 
was detected.
FGFR1 Inhibitor Sensitivity Is Related to  
CNG of the Gene
SCLC cells with higher copies of the FGFR1 gene, 
detected by real-time polymerase chain reaction assay, 
were more sensitive to PD173074, a pan-FGFR inhibitor 
(r = −0.79; p = 0.01) (Fig. 1C). Nevertheless, we failed to 
observe a correlation between the sensitivity to PD173074 
and FGFR1 mRNA expression (r = 0.45; p = 0.13) or FGFR1 
protein expression (Fig. 1C). The expression of p-FGFR 
was unrelated to the sensitivity to PD173074 (r = 0.31, 
p = 0.61). We studied the correlation between FGFR1 copy 
number (Supplementary Fig. S1A and B, Supplementary 
Digital Content 1, http://links.lww.com/JTO/A534) and 
FGFR1 mRNA expression (Supplementary Fig. S1C and D, 
Supplementary Digital Content 1, http://links.lww.com/JTO/
A534) and sensitivity to the cytotoxic agents cisplatin and eto-
poside, both of which are standard therapies for SCLC. We 
observed that SCLC cells expressing higher FGFR1 mRNA were 
more resistant to etoposide (r = 0.68; p = 0.01) (Supplementary 
Fig. S1D, Supplementary Digital Content 1, http://links.lww.
com/JTO/A534). Nevertheless, the protein expression of the 
FGFR1 gene was unrelated to the sensitivities to etoposide 
(r = 0.43, p = 0.29).
Focal Amplification of FGFR1 Gene Was 
Infrequent, But CNG Was Common
We studied, using FISH, whether the CNG was due to 
focal amplification or to polysomy of chromosome 8. Focal 
amplification was observed in only five of 68 tumor samples 
(7%) and among those high-level focal amplification was 
detected only in 1% (Fig. 2A).
Nevertheless, 22 of the 68 tumor samples (32%) dis-
played moderate amplification ranging from 4 to 9 FGFR1 
gene copy numbers per cell, which includes the entire chro-
mosome 8 (Table 1). The same pattern, that is, polysomy 
of chromosome 8, was seen in the SCLC cell lines H678 
and DMS114. We performed aCGH in five samples from the 
NCI cohort and observed CNG of the whole chromosome 
8p, implying polysomy in two samples (Fig. 2B and C). 
The results were consistent with what was observed by 
using FISH.
DISCUSSION
Recent large-scale sequencing efforts have identi-
fied FGFR1 as a potentially therapeutically tractable target 
in a subgroup of SCLC. Consistent with previous reports, 
we found no mutations in FGFR1 exons.11 Peifer et al.4 
detected focal amplification of FGFR1 locus in SCLC 
by copy number analysis (4 of 63, 6%) and validated the 
results by FISH in an independent cohort (3 of 51, 6%). 
Nevertheless, no amplification of the FGFR1 locus was 
identified in a similar analysis of 56 cases.3 Among 68 
SCLC tumor specimens, we found focal FGFR1 amplifica-
tion in 7% of the samples and true high-level amplification 
in only 1% of the sample. Our findings are comparable to 
results of large-scale integrated genomics studies where 
the frequency of FGFR1 amplification ranged from 0% to 
6%,3,4 and mutation was absent.
We found no correlation between FGFR1 copy num-
ber and mRNA expression and between FGFR1 copy num-
ber and protein expression. A similar lack of correlation 
between FGFR1 mRNA expression and copy number of 
the gene was also demonstrated in squamous cell carci-
nomas of lung.12 In SCLC cells, the lack of correlation 
between FGFR1 copy number, mRNA expression, and 
protein expression suggests that chromosome 8 polysomy 
may have little impact on FGFR1 expression. Despite 
SCLC cells with higher copies of the FGFR1 gene were 
more sensitive to PD173074, a non-isoform-specific FGFR 
inhibitor, we cannot exclude the possibility that other genes 
locating in the chromosome 8 contribute to the sensitivity 
to PD173074 in SCLC cells.
In conclusion, mutations or focal amplification of 
FGFR1 gene are rare in SCLC. Nevertheless, FGFR1 gene 
CNG is common and is related to sensitivity to FGFR inhibi-
tion. FGFR1 inhibitors should be explored in patients with 
SCLC with high copy numbers of the gene.
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